Transport des ARN : Questions médicales fréquentes
Nom anglais: RNA Transport
Descriptor UI:D034443
Tree Number:G03.143.850
Termes MeSH sélectionnés :
Cyclophosphamide
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Transport des ARN : Questions médicales les plus fréquentes",
"headline": "Transport des ARN : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Transport des ARN : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-19",
"dateModified": "2025-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Transport des ARN"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Transport biologique",
"url": "https://questionsmedicales.fr/mesh/D001692",
"about": {
"@type": "MedicalCondition",
"name": "Transport biologique",
"code": {
"@type": "MedicalCode",
"code": "D001692",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G03.143"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Transport des ARN",
"alternateName": "RNA Transport",
"code": {
"@type": "MedicalCode",
"code": "D034443",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Michael E Ward",
"url": "https://questionsmedicales.fr/author/Michael%20E%20Ward",
"affiliation": {
"@type": "Organization",
"name": "Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. wardme@nih.gov."
}
},
{
"@type": "Person",
"name": "Michael S Fernandopulle",
"url": "https://questionsmedicales.fr/author/Michael%20S%20Fernandopulle",
"affiliation": {
"@type": "Organization",
"name": "Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA."
}
},
{
"@type": "Person",
"name": "Jennifer Lippincott-Schwartz",
"url": "https://questionsmedicales.fr/author/Jennifer%20Lippincott-Schwartz",
"affiliation": {
"@type": "Organization",
"name": "Howard Hughes Medical Institute Janelia Research Campus, Ashburn, VA, USA. lippincottschwartzj@janelia.hhmi.org."
}
},
{
"@type": "Person",
"name": "Rowan P Herridge",
"url": "https://questionsmedicales.fr/author/Rowan%20P%20Herridge",
"affiliation": {
"@type": "Organization",
"name": "Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA."
}
},
{
"@type": "Person",
"name": "Jakub Dolata",
"url": "https://questionsmedicales.fr/author/Jakub%20Dolata",
"affiliation": {
"@type": "Organization",
"name": "Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma.",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36739175",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.transci.2023.103649"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35606478",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00520-022-07118-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36084276",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1200/JCO.22.00767"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.",
"datePublished": "2023-05-29",
"url": "https://questionsmedicales.fr/article/37300950",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jns.2023.120693"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.",
"datePublished": "2023-03-28",
"url": "https://questionsmedicales.fr/article/36990221",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtct.2023.03.028"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Métabolisme",
"item": "https://questionsmedicales.fr/mesh/D008660"
},
{
"@type": "ListItem",
"position": 3,
"name": "Transport biologique",
"item": "https://questionsmedicales.fr/mesh/D001692"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transport des ARN",
"item": "https://questionsmedicales.fr/mesh/D034443"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Transport des ARN - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Transport des ARN",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Transport des ARN",
"description": "Comment diagnostiquer un défaut de transport des ARN ?\nQuels tests sont utilisés pour évaluer le transport des ARN ?\nQuels marqueurs biologiques indiquent un problème de transport des ARN ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles de transport des ARN ?\nQuels symptômes peuvent indiquer un problème de transport des ARN ?",
"url": "https://questionsmedicales.fr/mesh/D034443?mesh_terms=Cyclophosphamide&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Transport des ARN",
"description": "Quels sont les symptômes d'un dysfonctionnement du transport des ARN ?\nLes troubles neurologiques sont-ils liés au transport des ARN ?\nComment le transport des ARN affecte-t-il le métabolisme ?\nY a-t-il des symptômes spécifiques aux maladies génétiques liées au transport des ARN ?\nLes troubles de l'humeur peuvent-ils être liés au transport des ARN ?",
"url": "https://questionsmedicales.fr/mesh/D034443?mesh_terms=Cyclophosphamide&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Transport des ARN",
"description": "Comment prévenir les troubles liés au transport des ARN ?\nLes dépistages génétiques peuvent-ils aider à prévenir les troubles des ARN ?\nY a-t-il des vaccins pour prévenir les troubles du transport des ARN ?\nL'éducation sur les maladies génétiques peut-elle aider à la prévention ?\nLes conseils génétiques sont-ils utiles pour prévenir les troubles des ARN ?",
"url": "https://questionsmedicales.fr/mesh/D034443?mesh_terms=Cyclophosphamide&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Transport des ARN",
"description": "Quels traitements existent pour les troubles du transport des ARN ?\nLa thérapie génique est-elle efficace pour les troubles de transport des ARN ?\nDes médicaments peuvent-ils améliorer le transport des ARN ?\nY a-t-il des approches nutritionnelles pour soutenir le transport des ARN ?\nLes thérapies physiques peuvent-elles aider en cas de troubles du transport des ARN ?",
"url": "https://questionsmedicales.fr/mesh/D034443?mesh_terms=Cyclophosphamide&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Transport des ARN",
"description": "Quelles complications peuvent survenir avec des troubles du transport des ARN ?\nLes troubles du transport des ARN peuvent-ils entraîner des maladies chroniques ?\nY a-t-il des risques de cancer associés aux troubles du transport des ARN ?\nLes complications peuvent-elles affecter la qualité de vie ?\nComment les complications sont-elles gérées dans ces troubles ?",
"url": "https://questionsmedicales.fr/mesh/D034443?mesh_terms=Cyclophosphamide&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Transport des ARN",
"description": "Quels sont les facteurs de risque pour les troubles du transport des ARN ?\nL'hérédité joue-t-elle un rôle dans les troubles du transport des ARN ?\nLes infections peuvent-elles affecter le transport des ARN ?\nLes carences nutritionnelles sont-elles un facteur de risque ?\nLe stress environnemental influence-t-il le transport des ARN ?",
"url": "https://questionsmedicales.fr/mesh/D034443?mesh_terms=Cyclophosphamide&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un défaut de transport des ARN ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de l'expression des gènes peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le transport des ARN ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'électrophorèse et la PCR peuvent aider à évaluer la qualité et la quantité d'ARN."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques indiquent un problème de transport des ARN ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux d'ARNm ou de protéines associées peuvent indiquer un dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles de transport des ARN ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser des anomalies dans le transport des ARN."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème de transport des ARN ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme la fatigue, des troubles neurologiques ou des anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un dysfonctionnement du transport des ARN ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, troubles cognitifs, et anomalies de croissance peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés au transport des ARN ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans le transport des ARN peuvent entraîner des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Comment le transport des ARN affecte-t-il le métabolisme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un transport inefficace des ARN peut perturber la synthèse des protéines et le métabolisme."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux maladies génétiques liées au transport des ARN ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des malformations congénitales peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur peuvent-ils être liés au transport des ARN ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre le transport des ARN et les troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés au transport des ARN ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Les dépistages génétiques peuvent-ils aider à prévenir les troubles des ARN ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage peut identifier les porteurs de mutations liées au transport des ARN."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir les troubles du transport des ARN ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour ces troubles."
}
},
{
"@type": "Question",
"name": "L'éducation sur les maladies génétiques peut-elle aider à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une meilleure compréhension des maladies génétiques peut aider à la prévention."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour prévenir les troubles des ARN ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent aider les familles à comprendre les risques et les options disponibles."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles du transport des ARN ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments ciblés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace pour les troubles de transport des ARN ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut corriger des défauts génétiques affectant le transport des ARN."
}
},
{
"@type": "Question",
"name": "Des médicaments peuvent-ils améliorer le transport des ARN ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent cibler les voies de transport des ARN pour améliorer leur fonction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches nutritionnelles pour soutenir le transport des ARN ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en nutriments essentiels peut soutenir la synthèse et le transport des ARN."
}
},
{
"@type": "Question",
"name": "Les thérapies physiques peuvent-elles aider en cas de troubles du transport des ARN ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent améliorer la fonction musculaire et neurologique affectée par ces troubles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles du transport des ARN ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques, neurologiques et de croissance."
}
},
{
"@type": "Question",
"name": "Les troubles du transport des ARN peuvent-ils entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent contribuer à des maladies chroniques comme des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés aux troubles du transport des ARN ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies dans le transport des ARN peuvent augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications liées aux troubles du transport des ARN peuvent gravement affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées dans ces troubles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique des soins multidisciplinaires pour traiter les symptômes et complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles du transport des ARN ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des mutations génétiques, des infections virales et des carences nutritionnelles."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les troubles du transport des ARN ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux troubles sont héréditaires et peuvent être transmis par les parents."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter le transport des ARN ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber le transport et la fonction des ARN."
}
},
{
"@type": "Question",
"name": "Les carences nutritionnelles sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des carences en vitamines et minéraux peuvent affecter le transport des ARN."
}
},
{
"@type": "Question",
"name": "Le stress environnemental influence-t-il le transport des ARN ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress environnemental peut affecter l'expression des gènes et le transport des ARN."
}
}
]
}
]
}
Although the incorporation of bortezomib into induction regimens has improved response rates in patients with multiple myeloma (MM), the role of bortezomib in the peripheral blood stem cell (PBSC) mob...
Cyclophosphamide is a commonly used cancer agent that is metabolically activated by polymorphic enzymes. This study aims to investigate the association between predicted activity of candidate pharmaco...
Genome-wide genetic data was collected from an institutional genetic data repository for CYP2B6, CYP3A4, CYP2C9, CYP2C19, GSTA1, GSTP1, ALDH1A1, ALDH3A1, ABCC1, ABCB1, and ERCC1. Treatment and toxicit...
In the primary analysis of 510 cyclophosphamide-treated patients with available genetic data, there was no difference in the odds of severe toxicity or treatment modification due to toxicity in CYP2B6...
The finding that patients who carry ALDH1A1 rs8187996 may have a lower risk of cyclophosphamide toxicity than wild-type patients contradicts a prior finding for this variant and should be viewed with ...
It remains controversial whether busulfan-based versus total body irradiation (TBI)-based regimens have comparable outcomes in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic he...
We performed an open-label, randomized phase III trial at 13 hospitals in China. Eligible patients (age 14-65 years) had standard-risk ALL in CR1. Patients were randomly assigned (1:1) to BuCy (0.8 mg...
Between January 2016 and February 2020, 275 patients were assigned to receive BuCy (273 assessed) and 275 to TBI-Cy (272 assessed). The 2-year overall survival was 76.6% (95% CI, 71.7 to 81.8) and 79....
The BuCy regimen has noninferior efficiency and safety as TBI-Cy (4.5 Gy × 2) for patients with adult standard-risk B cell-ALL in CR1 undergoing HLA-matched allo-HSCT....
Cyclophosphamide (CYC) may be an effective treatment in patients who fail first line therapy for severe central nervous system (CNS) inflammatory disorders including CNS vasculitis, neuromyelitis opti...
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a serious life-threatening complication. The granulocyte colony-stimulated factor mobilized donor lymphocyte infusions (...
To explore this possibility, a retrospective study was conducted. 20 patients relapsing after HSCT were administered 20 mg/kg/d cyclophosphamide(Cy)on day 3 (for matched related transplantation) or on...
With a median follow-up of 4.8 (0-37.1) months, the PDCy group had lower cumulative incidence of severe aGVHD (III-IV, 5 % vs 31 %, p = 0.02; II-IV, 25 % vs 52 %, p = 0.04), but no significant differe...
On the premise of safety, the PDCy regimen could effectively protest against severe aGVHD after gDLI while preserving therapeutic response rates. However, the research results still require verificati...
Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches t...
Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tu...
Initial treatment with four cycles of EC reduced circulating B and T cells by 94% and 45%, respectively. In contrast, no comparable effects on lymphocytes were observed in patients treated with initia...
The deleterious effect of EC on lymphocytes indicates strong immunosuppressive properties of this combination therapy. D, in contrast, has no effect on lymphocytes, but triggers the secretion of stimu...
High-dose total body irradiation (TBI) is considered a cornerstone of myeloablative conditioning for allogeneic stem cell transplantation (allo-SCT). We retrospectively compared the main outcomes of a...
Fifty-nine patients received cyclophosphamide (Cy)-TBI (13.5 Gy) and graft-versus-host disease (GVHD) prophylaxis with a calcineurin-inhibitor plus methrotrexate (CyTBI group) and 28 patients received...
Median follow-up for survivors was 82 and 22 months. The 12-month probability of overall survival and progression-free survival were similar (p = .18, p = .7). The incidence of Grades 2-4 and 3-4 acut...
The study confirms the safety and efficacy of a novel FluTBI-PTCy platform with reduced incidence of severe acute and chronic GVHD, and early improvement of NRM....
Patients receiving immune checkpoint inhibitors have been reported to develop autoimmune endocrine diseases, including type 1 diabetes, although few drugs have been shown to induce type 1 diabetes. Ad...
A 54-year-old Filipino female patient underwent surgery for left-sided breast cancer. Postoperative chemotherapy was initiated, including doxorubicin (Adriamycin) and cyclophosphamide therapy. The pat...
The present case shows that doxorubicin and cyclophosphamide therapy may cause unexpected adverse responses, such as type 1 diabetes, though rarely, and highlights the importance of careful patient fo...
Because nanomaterials are highly reactive and electronically sensitive towards a variety of drug molecules, they are thought of as efficient drug sensors. In the present research study, an aluminum ca...